Defects in Androgen Biosynthesis Causing 46,XY Disorders of Sexual Development

Richard J. Auchus; Walter L. Miller

doi:10.1055/s-0032-1324726

Seminars in Reproductive Medicine, Inhaltsverzeichnis

Semin Reprod Med 2012; 30(05): 417-426
DOI: 10.1055/s-0032-1324726

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Defects in Androgen Biosynthesis Causing 46,XY Disorders of Sexual Development

Richard J. Auchus

¹Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine and the Program for Disorders of Sexual Development, University of Michigan, Ann Arbor, Michigan

,

Walter L. Miller

²Division of Endocrinology, Department of Pediatrics, University of California, San Francisco, San Francisco, California

› Institutsangaben

Abstract

At least one genetic defect in each reaction of the classical androgen biosynthesis pathway has been described. For some steps, such as the conversion of cholesterol to pregnenolone and the 17,20-lyase reaction, two or three genetic defects cause similar disorders with overlapping phenotypes and biochemical profiles. The elucidation of the molecular basis for these diseases has helped to define the pathways, essential genes, and enzymatic steps required to make androgens, and this knowledge is being exploited to develop better treatments of androgen-dependent diseases. Furthermore the description of nonclassical lipoid CAH and the protean manifestations of P450 oxidoreductase (POR) deficiencies has expanded the spectrum of human disease caused by disordered steroidogenesis. Finally, the recognition of the backdoor pathway to DHT has added a new dimension to our understanding of how steroid flux is maintained in normal and pathologic states.

The traditional view of male external genital development has been that fetal testicular testosterone is converted to DHT by 5α-reductase Type 2 in genital skin, which then acts in a paracrine fashion to stimulate fusion of the labio-scrotal folds and phallic growth. This view is consistent with the incomplete external genital development in persons with severe deficiencies of 5α-reductase type 2. The new observations concerning AKR1C2/4 and the backdoor pathway indicate that DHT produced in the testis via the backdoor pathway also acts as a hormone to induce labio-scrotal fusion. Thus, both the classic and backdoor pathways are needed, and DHT acts in male genital development as both a paracrine factor and as a hormone. These surprising findings are revising our understanding of the mechanisms by which male sexual differentiation occurs, and illustrate the importance of detailed studies of rare patients with 46,XY DSD.

Keywords

androgen - testosterone - 46,XY DSD - congenital adrenal hyperplasia - testis - steroid - steroidogenesis - enzyme

Volltext

Referenzen

References
1 Jost A. Recherches sur la differenciation sexuelle de l'embryon de lapin. Arch Anat Microsc Morphol Exp 1947; 36: 117-121
2 Jost A, Vigier B, Prépin J, Perchellet JP. Studies on sex differentiation in mammals. Recent Prog Horm Res 1973; 29: 1-41
3 Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011; 32 (1) 81-151
4 Wilson JD, Lasnitzki I. Dihydrotestosterone formation in fetal tissues of the rabbit and rat. Endocrinology 1971; 89 (3) 659-668
5 Thigpen AE, Davis DL, Milatovich A , et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 1992; 90 (3) 799-809
6 Wilson JD, Auchus RJ, Leihy MW , et al. 5α-androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology 2003; 144 (2) 575-580
7 Flück CE, Meyer-Böni M, Pandey AV , et al. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet 2011; 89 (2) 201-218
8 Agarwal AK, Auchus RJ. Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 2005; 146 (6) 2531-2538
9 Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res 2011; 52 (12) 2111-2135
10 Miller WL. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim Biophys Acta 2007; 1771 (6) 663-676
11 Lin D, Sugawara T, Strauss III JF , et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995; 267 (5205) 1828-1831
12 Bose HS, Sugawara T, Strauss III JF, Miller WL ; International Congenital Lipoid Adrenal Hyperplasia Consortium. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996; 335 (25) 1870-1878
13 Bose HS, Sato S, Aisenberg J, Shalev SA, Matsuo N, Miller WL. Mutations in the steroidogenic acute regulatory protein (StAR) in six patients with congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85 (10) 3636-3639
14 Chen X, Baker BY, Abduljabbar MA, Miller WL. A genetic isolate of congenital lipoid adrenal hyperplasia with atypical clinical findings. J Clin Endocrinol Metab 2005; 90 (2) 835-840
15 Kim JM, Choi JH, Lee JH , et al. High allele frequency of the p.Q258X mutation and identification of a novel mis-splicing mutation in the STAR gene in Korean patients with congenital lipoid adrenal hyperplasia. Eur J Endocrinol 2011; 165 (5) 771-778
16 Bose HS, Pescovitz OH, Miller WL. Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 1997; 82 (5) 1511-1515
17 Fujieda K, Tajima T, Nakae J , et al. Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. J Clin Invest 1997; 99 (6) 1265-1271
18 Baker BY, Lin L, Kim CJ , et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006; 91 (12) 4781-4785
19 Metherell LA, Naville D, Halaby G , et al. Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab 2009; 94 (10) 3865-3871
20 Khoury K, Barbar E, Ainmelk Y, Ouellet A, Lehoux JG. Gonadal function, first cases of pregnancy, and child delivery in a woman with lipoid congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94 (4) 1333-1337
21 Sertedaki A, Pantos K, Vrettou C , et al. Conception and pregnancy outcome in a patient with 11-bp deletion of the steroidogenic acute regulatory protein gene. Fertil Steril 2009; 91 (3) 934-918 , e15–e18
22 Yang X, Iwamoto K, Wang M, Artwohl J, Mason JI, Pang S. Inherited congenital adrenal hyperplasia in the rabbit is caused by a deletion in the gene encoding cytochrome P450 cholesterol side-chain cleavage enzyme. Endocrinology 1993; 132 (5) 1977-1982
23 Hu MC, Hsu NC, El Hadj NB , et al. Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1. Mol Endocrinol 2002; 16 (8) 1943-1950
24 Csapo AI, Pulkkinen MO. Indispensibility of the human corpus luteum in the maintenance of early pregnancy: Luteectomy evidence. Obstet Gynecol Surv 1978; 33 (2) 69-81
25 Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115 (6) 759-765
26 Tajima T, Fujieda K, Kouda N, Nakae J, Miller WL. Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 2001; 86 (8) 3820-3825
27 Katsumata N, Ohtake M, Hojo T , et al. Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J Clin Endocrinol Metab 2002; 87 (8) 3808-3813
28 Hiort O, Holterhus PM, Werner R , et al. Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure. J Clin Endocrinol Metab 2005; 90 (1) 538-541
29 al Kandari H, Katsumata N, Alexander S, Rasoul MA. Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. J Clin Endocrinol Metab 2006; 91 (8) 2821-2826
30 Kim CJ, Lin L, Huang N , et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 2008; 93 (3) 696-702
31 Parajes S, Kamrath C, Rose IT , et al. A novel entity of clinically isolated adrenal insufficiency caused by a partially inactivating mutation of the gene encoding for P450 side chain cleavage enzyme (CYP11A1). J Clin Endocrinol Metab 2011; 96 (11) E1798-E1806
32 Rubtsov P, Karmanov M, Sverdlova P, Spirin P, Tiulpakov A. A novel homozygous mutation in CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46,XY patient. J Clin Endocrinol Metab 2009; 94 (3) 936-939
33 Sahakitrungruang T, Tee MK, Blackett PR, Miller WL. Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 2011; 96 (3) 792-798
34 Auchus RJ, Lee TC, Miller WL. Cytochrome b ₅ augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998; 273 (6) 3158-3165
35 Onoda M, Hall PF. Cytochrome b ₅ stimulates purified testicular microsomal cytochrome P-450 (C21 side-chain cleavage). Biochem Biophys Res Commun 1982; 108 (2) 454-460
36 Katagiri M, Kagawa N, Waterman MR. The role of cytochrome b₅ in the biosynthesis of androgens by human P450c17. Arch Biochem Biophys 1995; 317 (2) 343-347
37 Lee-Robichaud P, Wright JN, Akhtar ME, Akhtar M. Modulation of the activity of human 17α-hydroxylase-17,20-lyase (CYP17) by cytochrome b ₅: endocrinological and mechanistic implications. Biochem J 1995; 308 (Pt 3) 901-908
38 Suzuki T, Sasano H, Takeyama J , et al. Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clin Endocrinol (Oxf) 2000; 53 (6) 739-747
39 Naffin-Olivos JL, Auchus RJ. Human cytochrome b ₅ requires residues E48 and E49 to stimulate the 17,20-lyase activity of cytochrome P450c17. Biochemistry 2006; 45 (3) 755-762
40 Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001; 30 (1) 101-119 , vii
41 Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. J Clin Invest 1966; 45 (12) 1946-1954
42 Kater CE, Biglieri EG. Disorders of steroid 17α-hydroxylase deficiency. Endocrinol Metab Clin North Am 1994; 23 (2) 341-357
43 Martin RM, Lin CJ, Costa EM , et al. P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J Clin Endocrinol Metab 2003; 88 (12) 5739-5746
44 Costa-Santos M, Kater CE, Auchus RJ ; Brazilian Congenital Adrenal Hyperplasia Multicenter Study Group. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17α-hydroxylase deficiency. J Clin Endocrinol Metab 2004; 89 (1) 49-60
45 Attard G, Reid AH, Yap TA , et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26 (28) 4563-4571
46 Attard G, Reid AHM, Auchus RJ , et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012; 97 (2) 507-516
47 Nakajin S, Shively JE, Yuan PM, Hall PF. Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17α-hydroxylase and c17,20-lyase) associated with one protein. Biochemistry 1981; 20 (14) 4037-4042
48 Zuber MX, Simpson ER, Waterman MR. Expression of bovine 17α-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science 1986; 234 (4781) 1258-1261
49 Geller DH, Auchus RJ, Mendonça BB, Miller WL. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997; 17 (2) 201-205
50 Geller DH, Auchus RJ, Miller WL. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol 1999; 13 (1) 167-175
51 Van Den Akker EL, Koper JW, Boehmer AL , et al. Differential inhibition of 17α-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab 2002; 87 (12) 5714-5721
52 Sherbet DP, Tiosano D, Kwist KM, Hochberg Z, Auchus RJ. CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J Biol Chem 2003; 278 (49) 48563-48569
53 Tiosano D, Knopf C, Koren I , et al. Metabolic evidence for impaired 17α-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity. Eur J Endocrinol 2008; 158 (3) 385-392
54 Arlt W, Walker EA, Draper N , et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363 (9427) 2128-2135
55 Flück CE, Tajima T, Pandey AV , et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36 (3) 228-230
56 Huang N, Pandey AV, Agrawal V , et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76 (5) 729-749
57 Sahakitrungruang T, Huang N, Tee MK , et al. Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. J Clin Endocrinol Metab 2009; 94 (12) 4992-5000
58 Hershkovitz E, Parvari R, Wudy SA , et al. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J Clin Endocrinol Metab 2008; 93 (9) 3584-3588
59 Giordano SJ, Kaftory A, Steggles AW. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Hum Genet 1994; 93 (5) 568-570
60 Kok RC, Timmerman MA, Wolffenbuttel KP, Drop SL, de Jong FH. Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X. J Clin Endocrinol Metab 2010; 95 (3) 994-999
61 Miller WL. The syndrome of 17,20 lyase deficiency. J Clin Endocrinol Metab 2012; 97 (1) 59-67
62 Bongiovanni AM. The adrenogenital syndrome with deficiency of 3β-hydroxysteroid dehydrogenase. J Clin Invest 1962; 41: 2086-2092
63 Pang S. The molecular and clinical spectrum of 3beta-hydroxysteroid dehydrogenase deficiency disorder. Trends Endocrinol Metab 1998; 9 (2) 82-86
64 Lorence MC, Corbin CJ, Kamimura N, Mahendroo MS, Mason JI. Structural analysis of the gene encoding human 3β-hydroxysteroid dehydrogenase/Δ^5→4-isomerase. Mol Endocrinol 1990; 4 (12) 1850-1855
65 Lorence MC, Murry BA, Trant JM, Mason JI. Human 3β-hydroxysteroid dehydrogenase/Δ^5→4 isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 1990; 126 (5) 2493-2498
66 Rhéaume E, Lachance Y, Zhao HF , et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3β-hydroxysteroid dehydrogenase/Δ⁵-Δ⁴-isomerase in human adrenals and gonads. Mol Endocrinol 1991; 5 (8) 1147-1157
67 Lachance Y, Luu-The V, Verreault H , et al. Structure of the human type II 3β-hydroxysteroid dehyrdrogenase/Δ⁵-Δ⁴ isomerase (3β-HSD) gene: adrenal and gonadal specificity. DNA Cell Biol 1991; 10: 701-711
68 Rhéaume E, Simard J, Morel Y , et al. Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene. Nat Genet 1992; 1 (4) 239-245
69 Moisan AM, Ricketts ML, Tardy V , et al. New insight into the molecular basis of 3β-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab 1999; 84 (12) 4410-4425
70 Cara JF, Moshang Jr T, Bongiovanni AM, Marx BS. Elevated 17-hydroxyprogesterone and testosterone in a newborn with 3β-hydroxysteroid dehydrogenase deficiency. N Engl J Med 1985; 313 (10) 618-621
71 Nordenström A, Forest MG, Wedell A. A case of 3β-hydroxysteroid dehydrogenase type II (HSD3B2) deficiency picked up by neonatal screening for 21-hydroxylase deficiency: difficulties and delay in etiologic diagnosis. Horm Res 2007; 68 (4) 204-208
72 Lutfallah C, Wang W, Mason JI , et al. Newly proposed hormonal criteria via genotypic proof for type II 3β-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87 (6) 2611-2622
73 Marui S, Castro M, Latronico AC , et al. Mutations in the type II 3β-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clin Endocrinol (Oxf) 2000; 52 (1) 67-75
74 Marui S, Russell AJ, Paula FJ, Dick-de-Paula I, Marcondes JA, Mendonca BB. Genotyping of the type II 3β-hydroxysteroid dehydrogenase gene (HSD3B2) in women with hirsutism and elevated ACTH-stimulated Δ⁵-steroids. Fertil Steril 2000; 74 (3) 553-557
75 Carbunaru G, Prasad P, Scoccia B , et al. The hormonal phenotype of Nonclassic 3β-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab 2004; 89 (2) 783-794
76 Mermejo LM, Elias LL, Marui S, Moreira AC, Mendonca BB, de Castro M. Refining hormonal diagnosis of type II 3β-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 2005; 90 (3) 1287-1293
77 Labrie F, Luu-The V, Lin SX, Simard J, Labrie C. Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab 2000; 11 (10) 421-427
78 Geissler WM, Davis DL, Wu L , et al. Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nat Genet 1994; 7 (1) 34-39
79 Moghrabi N, Hughes IA, Dunaif A, Andersson S. Deleterious missense mutations and silent polymorphism in the human 17β-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab 1998; 83 (8) 2855-2860
80 Boehmer AL, Brinkmann AO, Sandkuijl LA , et al. 17β-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab 1999; 84 (12) 4713-4721
81 Ahmed SF, Cheng A, Dovey L , et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85 (2) 658-665
82 Lee YS, Kirk JM, Stanhope RG , et al. Phenotypic variability in 17β-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls. Clin Endocrinol (Oxf) 2007; 67 (1) 20-28
83 Andersson S, Geissler WM, Wu L , et al. Molecular genetics and pathophysiology of 17β-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 1996; 81 (1) 130-136
84 McKeever BM, Hawkins BK, Geissler WM , et al. Amino acid substitution of arginine 80 in 17β-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics. Biochim Biophys Acta 2002; 1601 (1) 29-37
85 Walter KN, Kienzle FB, Frankenschmidt A , et al. Difficulties in diagnosis and treatment of 5α-reductase type 2 deficiency in a newborn with 46,XY DSD. Horm Res Paediatr 2010; 74 (1) 67-71
86 Faisal Ahmed S, Iqbal A, Hughes IA. The testosterone:androstenedione ratio in male undermasculinization. Clin Endocrinol (Oxf) 2000; 53 (6) 697-702
87 Mendonca BB, Inacio M, Arnhold IJ , et al. Male pseudohermaphroditism due to 17β-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000; 79 (5) 299-309
88 Chang KH, Li R, Papari-Zareei M , et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011; 108 (33) 13728-13733
89 Gupta MK, Guryev OL, Auchus RJ. 5α-reduced C₂₁ steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003; 418 (2) 151-160
90 Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15 (9) 432-438
91 Homma K, Hasegawa T, Nagai T , et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 2006; 91 (7) 2643-2649
92 Zachmann M, Völlmin JA, Hamilton W, Prader A. Steroid 17,20-desmolase deficiency: a new cause of male pseudohermaphroditism. Clin Endocrinol (Oxf) 1972; 1 (4) 369-385